Search results
Results from the WOW.Com Content Network
Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [45] [4] [43] [44] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. [8]
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
Medroxyprogesterone acetate is the generic name of the drug and its INN Tooltip INN, USAN Tooltip United States Adopted Name, BAN Tooltip BANM, and JAN Tooltip Japanese Accepted Name, while medrossiprogesterone is the DCIT Tooltip Denominazione Comune Italiana and médroxyprogestérone the DCF Tooltip Dénomination Commune Française of its ...
Depot injections can be created by modifying the drug molecule itself, as in the case of prodrugs, or by modifying the way it is administered, as in the case of oil/lipid suspensions. Depot injections can have a duration of action of one month or greater and are available for many types of drugs, including antipsychotics and hormones.
Estradiol cypionate/medroxyprogesterone acetate (EC/MPA), sold under the brand name Cyclofem among others, is a form of combined injectable birth control. [2] It contains estradiol cypionate (EC), an estrogen, and medroxyprogesterone acetate (MPA), a progestin. [2] It is recommended for short-term use and is given once a month by injection into ...
Average number of moderate-to-severe hot flashes per week with placebo and different doses of oral estradiol in menopausal women [40] [41]. Estradiol is used in menopausal hormone therapy to prevent and treat moderate to severe menopausal symptoms such as hot flashes, vaginal dryness and atrophy, and osteoporosis (bone loss). [11]
The leuprorelin is given by intramuscular injection and the norethisterone acetate is taken by mouth. [1] The co-packaged medication was approved for medical use in the United States in December 2012. [2]
Primary indications include endometriosis, [5] for the reduction of uterine fibroids, to treat prostate cancer, and to treat male hypersexuality with severe sexual deviation. [4] The drug has also been used off label to delay puberty in patients with gender dysphoria. [6] It was patented in 1975 and approved for medical use in 1986. [7]